Forbes -
3 Jun 2021 16:30

Messenger RNA technology leaders Moderna and BioNTech have seen their stocks rally by around 75% and 150% respectively year-to-date driven by strong demand for their Covid-19 shots and also as investors see tremendous potential in leveraging mRNA technology beyond Covid, to fight a variety of...
Share this Article